WASHINGTON, DC (February 13, 2020) — Avalere's latest findings add to the growing body of evidence that Medicare Part D Plans are discouraging the use of lower-cost generic drugs. For the first time there are more generics on non-generic tiers. This forces America’s patients to pay more for their generic drugs and causes higher taxpayer spending by reducing generic substitution, even as the Administration pledges to reduce drug costs for patients. We encourage the Administration and Congress to update Medicare policies to promote the use of lower-cost generics.
ATTRIBUTE TO: Craig Burton, Vice President of Policy
MEDIA CONTACT:
Rachel Schwartz
202.249.7147
About AAM
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 22 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.